COVID-19 in individuals with sickle cell disease/trait compared with other Black individuals

Singh, Ashima; Brandow, Amanda M.; Panepinto, Julie A.

doi:10.1182/bloodadvances.2020003741

Cited by 66 publications

(88 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, SCD patients could have other severe outcomes not evaluated here (e.g., pain or pneumonia). 12 The mortality rate in our SCD patients (6%-8%) is comparable to those reported in the US 6 and UK registries 13 (7.3% and 8.4%, respectively). Singh et al 12 found that Black individuals with SCD were more likely to be hospitalized and to develop pneumonia and pain, but no differences in mortality rate compared to matched Black individuals without SCD/SCT were observed, consistent with our findings.…”

supporting

confidence: 83%

Individuals with sickle cell disease and sickle cell trait demonstrate no increase in mortality or critical illness from COVID-19 - a fifteen hospital observational study in the Bronx, New York

et al. 2021

View full text Add to dashboard Cite

show abstract

supporting

confidence: 83%

Individuals with sickle cell disease and sickle cell trait demonstrate no increase in mortality or critical illness from COVID-19 - a fifteen hospital observational study in the Bronx, New York

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The higher morbidity and mortality from SARS-CoV-2 infection in African Americans are well documented. Overall, this study showed no difference in morbidity or mortality outcomes between individuals with and without SCT among patients admitted for SARS-CoV-2 infection, which mirrors the results from International Classification of Diseases, Tenth Revision code analysis by Singh et al 7 However, there were a few notable differences between the 2 groups. At the time of admission, individuals with SCT had significantly higher creatinine (median: 2.06 vs 1.15; P = .004) and lower EGFR ( P = .014) than those without SCT, consistent with the known higher rates of EGFR decline in patients with SCT.…”

Section: Resultssupporting

confidence: 86%

Impact of sickle cell trait on morbidity and mortality from SARS-CoV-2 infection

et al. 2021

View full text Add to dashboard Cite

The COVID-19 pandemic has highlighted racial health disparities within the United States. Although social determinants of health are the most likely drivers of this disparity, it is possible that genetic traits enriched in the black population like sickle cell trait (SCT) could worsen the morbidity and mortality of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients admitted for SARS-CoV-2 infection who identified as black or African American were included in the study (n = 166). Blood remnants were tested for SCT, and clinical data were abstracted from the chart. There was no difference in mortality between those with SCT and those without. There was no difference in respiratory complications between groups, but those without SCT had a much higher burden of chronic lung disease (P = .004). Those with SCT had higher creatinine on admission (P = .004), but no difference in in-hospital renal complications (P = .532). Notably, 12% of the cohort had SCT, which is higher than the expected 7.31% (P = .025). Our study did not show any evidence of increased end organ damage, morbidity, or mortality from SARS-CoV-2 infection among patients with SCT but did show differences in admission creatinine and preexisting lung disease.

show abstract

“…Other reports did not identify SCD as a risk factor for COVID-19 (32)(33)(34), or COVID-19 as a risk factor for SCD-mediated vaso-oclusive crisis (35). Nevertheless, patients with SCD have a predisposition to the development of pulmonary hypertension and chronic kidney disease (36).…”

Section: Discussionmentioning

confidence: 99%

Long‑term effects of COVID‑19 in sickle cell disease: A case report

et al. 2021

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can generate a respiratory and systemic disease known as coronavirus disease 2019 (COVID-19). To date, at least to the best of our knowledge, only a limited number of studies have identified SARS-CoV-2 infection in patients with sickle cell disease (SCD). Due to the lack of knowledge of the long-term effects of COVID-19, the present study presents the hematological alterations in a patient with SCD during hospitalization due to COVID-19 and for up to 180 days following SARS-CoV-2 clearance and hospital discharge. The present study describes the case of a patient with SCD who was diagnosed with moderate COVID-19 infection, without the need for invasive mechanical ventilation. Following SARS-CoV-2 clearance, long-term (6 months) follow-up identified an increase in the reticulocyte frequency, creatinine and D-dimer levels. On the whole, the present study manuscript presents the case of a patient with moderate COVID-19 infection with long-term laboratory alterations at even 6 months following SARS-CoV-2 clearance. Further investigations are required however, to focus on the long-term evaluations in patients who have recovered from COVID-19, in order to fully determine the extension of possible sequelae.

show abstract

COVID-19 in individuals with sickle cell disease/trait compared with other Black individuals

Cited by 66 publications

References 26 publications

Individuals with sickle cell disease and sickle cell trait demonstrate no increase in mortality or critical illness from COVID-19 - a fifteen hospital observational study in the Bronx, New York

Individuals with sickle cell disease and sickle cell trait demonstrate no increase in mortality or critical illness from COVID-19 - a fifteen hospital observational study in the Bronx, New York

Impact of sickle cell trait on morbidity and mortality from SARS-CoV-2 infection

Long‑term effects of COVID‑19 in sickle cell disease: A case report

Contact Info

Product

Resources

About